Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation increases morbidity and mortality. Nitric oxide inhalation (NOi) is frequently used to prevent and treat RVF. However, the criteria to wean of and stop NOi are not fully standardized. We analyzed the risk factors of re-start of NO inhalation after LVAD implantation. We clarified that CVP (central venous pressure) and CVP/dPAP (diastolic pulmonary pressure) ratio were the risk factors of re-start of NOi (recurrence of RVF). Also, we showed that restart of NOi decreases ventilator-free days within 28 days and increases ICU length of stay.
|